Clofarabine in pediatric acute leukemia: Current findings and issues

Nobuko Hijiya*, Elly Barry, Robert J. Arceci

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Clofarabine is a second-generation purine nucleoside analog and has significant anti-leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA-damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians.

Original languageEnglish (US)
Pages (from-to)417-422
Number of pages6
JournalPediatric Blood and Cancer
Issue number3
StatePublished - Sep 1 2012


  • ALL
  • Clofarabine
  • New agent
  • Relapse

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Clofarabine in pediatric acute leukemia: Current findings and issues'. Together they form a unique fingerprint.

Cite this